

**aprepitant 80 mg dual pack**  
**EMEND Dual Pack**

**Diagnoses Considered for Coverage:**

- Prevention of chemotherapy-induced nausea and vomiting (CINV)
- Prevention of radiation therapy-induced nausea and vomiting (RINV)

**Coverage Criteria:**

**For diagnosis listed above:**

- Medical rationale why patient is unable to use the aprepitant (Emend) Tri Pack, **and**
- Dose does not exceed one dual-pack per cancer drug (chemotherapy) cycle.

**Coverage Duration:** *duration of chemotherapy or radiation*

**For brand-name Emend 80 mg Dual Pack:**

- Meets above coverage criteria for generic, **and**
- Allergic or intolerable side effect to the generic formulation

**Coverage Duration:** One time

Effective: 9/01/2020